These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16402383)

  • 1. Coxibs and Alzheimer's disease: should they stay or should they go?
    Firuzi O; Praticò D
    Ann Neurol; 2006 Feb; 59(2):219-28. PubMed ID: 16402383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors.
    Giovannini MG; Scali C; Prosperi C; Bellucci A; Pepeu G; Casamenti F
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):31-40. PubMed ID: 14552702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs.
    Townsend KP; Praticò D
    FASEB J; 2005 Oct; 19(12):1592-601. PubMed ID: 16195368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells.
    Ferrera P; Arias C
    Neurochem Int; 2005 Dec; 47(8):589-96. PubMed ID: 16169124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action.
    Gasparini L; Ongini E; Wenk G
    J Neurochem; 2004 Nov; 91(3):521-36. PubMed ID: 15485484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease.
    Imbimbo BP
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1147-68. PubMed ID: 19589092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of inducible cyclooxygenase (COX-2) in inflammation.
    Seibert K; Masferrer JL
    Receptor; 1994; 4(1):17-23. PubMed ID: 8038702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into COX-2 biology and inhibition.
    Patrignani P; Tacconelli S; Sciulli MG; Capone ML
    Brain Res Brain Res Rev; 2005 Apr; 48(2):352-9. PubMed ID: 15850674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
    Coruzzi G; Venturi N; Spaggiari S
    Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease.
    Gasparini L; Ongini E; Wilcock D; Morgan D
    Brain Res Brain Res Rev; 2005 Apr; 48(2):400-8. PubMed ID: 15850679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid beta peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes.
    Hüll M; Müksch B; Akundi RS; Waschbisch A; Hoozemans JJ; Veerhuis R; Fiebich BL
    Neurochem Int; 2006 Jun; 48(8):663-72. PubMed ID: 16546299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
    Kashfi K; Rigas B
    Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
    Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI
    Neuroscience; 2006 Sep; 141(3):1149-62. PubMed ID: 16753269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia.
    Pasinetti GM
    J Alzheimers Dis; 2002 Oct; 4(5):435-45. PubMed ID: 12446975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alzheimer's disease: from brain lesions to new drugs].
    Forette F; Hauw JJ
    Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible anti-inflammatory role of COX-2-derived prostaglandins: implications for inflammation research.
    Kapoor M; Shaw O; Appleton I
    Curr Opin Investig Drugs; 2005 May; 6(5):461-6. PubMed ID: 15912958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives.
    Cipollone F; Cicolini G; Bucci M
    Pharmacol Ther; 2008 May; 118(2):161-80. PubMed ID: 18420277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.